touchRESPIRATORY caught up with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss his analysis of phase 3 trials of gefapixant in chronic cough.
The abstract ‘Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant‘ was presented at AAAAI 2022, 25-28 February.
Questions
- What have the COUGH-1 and COUGH-2 studies taught us about the efficacy and safety of gefapixant in patients with RCC or UCC? (0:20)
- What were the aims of the current comparison of baseline characteristics and treatment efficacy in patients in these two studies? (1:49)
- What questions remain unanswered? (3:22)
Disclosures: Michael Blaiss discloses consulting for Merck and Bellus, serving on advisory boards for Merck and Bellus, and participating in Speaker’s Bureaus for Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAAAI meeting 2022
